US OptionsDetailed Quotes
VYGR241115C10000
- 0.05
- -0.10-66.67%
15min DelayClose Nov 1 16:00 ET
0.05High0.05Low
0.05Open0.15Pre Close9 Volume4.03K Open Interest10.00Strike Price45.00Turnover121.49%IV43.57%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0758Delta0.0889Gamma140.00Leverage Ratio-0.0086Theta0.0002Rho10.61Eff Leverage0.0019Vega
Voyager Therapeutics Stock Discussion
Sign in to post a comment
$Voyager Therapeutics (VYGR.US)$ I got in on this around April of this year for around $6.30-6.40 and have been holding it just waiting for it to completely crash. I'm not sure exactly what caused the uptick today but I do know I'm extremely tempted to sell it all off and take the smaller profits (actually I'm definitely going to sell some for that), but I'm not sure, I think this company still has potential long-term, I was just blown away by how stagnant it had been for months. Anyone else have...
2
3
$Voyager Therapeutics (VYGR.US)$
This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up
This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up
$Voyager Therapeutics (VYGR.US)$ Press Release: Voyager Enters Into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Dow Jones· 2 mins ago
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties
Dow Jones· 2 mins ago
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties
2
$Voyager Therapeutics (VYGR.US)$
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...
1
$Voyager Therapeutics (VYGR.US)$
Looks like 6 holds the big buy but we shall see. Don't expect it to get much lower.
Looks like 6 holds the big buy but we shall see. Don't expect it to get much lower.
1
$Voyager Therapeutics (VYGR.US)$ Man, I've been holding this for awhile (since late Q1 this year) and it just can't ever seem to get that boost and then that second boost that I was really expecting to come by the end of summer. I guess there's still time and I'm only in @ $7.15 or so, so it could definitely be worse. I'm still expecting this to take off at some point.
$Voyager Therapeutics (VYGR.US)$ Finally some movement on this one I bought in at just under $8 a few months ago and have just been holding while this has seemly remained stagnant. Hopefully today's movement is a nice sign of what is to come 😁.
4
1
$Voyager Therapeutics (VYGR.US)$ Benzinga· 2 mins ago
Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
$Voyager Therapeutics (VYGR.US)$ Voyager Therapeutics To Present Translational Data For IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials At ASGCT 27th Annual Meeting
$Voyager Therapeutics (VYGR.US)$ Voyager Therapeutics And Neurocrine Biosciences Have Selected Lead Development Candidate In GBA1 Gene Therapy Program For Potential Treatment Of Parkinson's Disease And Other GBA1-mediated Diseases. Triggers 3 million milestone payment
No comment yet
climbing capybara : similar thoughts especially when yesterday i was down 15% but since company is doing great financially, decided to hold and wait.
BeeDeeVee712 OP climbing capybara : You literally described the back and forth I've been having in my head...I don't get why it hasn't moved (technically has dropped) after looking through and following up on their financials, they seem rather strong and I'm not really finding any sufficient reason to explain the lack of growth, especially over a period of months, you know?
climbing capybara : yup totally get you. feeling some opportunity loss and been thining if i should move on to a stock with more volume